Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT02612311
Title Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia
Acronym UNITY-CLL
Recruitment Terminated
Gender both
Phase Phase III
Variant Requirements No
Sponsors TG Therapeutics, Inc.
Indications
Therapies
Age Groups: adult
Covered Countries USA | POL | ITA | ISR | GBR | ESP


No variant requirements are available.